$NMTC
NEUROONE MEDICAL TECHNOLOGIES Corp Stock $nmtc

$nmtc Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-K Financial Statement

#000121390023096120 Filed on December 15, 2023

Income Statement

Concept	2023 Q4	2023 Q3	2023
Revenue	$977.6K	$782.5K	$1.952M
YoY Change	753.25%	-61.09%	1040.65%
Cost Of Revenue	$711.3K	$548.1K	$1.496M
YoY Change	460.61%	553.7%	518.24%
Gross Profit	$266.3K	$234.4K	$456.5K
YoY Change	-2263.92%	-87.84%	-744.85%
Gross Profit Margin	27.24%	29.95%	23.38%
Selling, General & Admin	$2.173M	$1.579M	$6.926M
YoY Change	30.64%	-16.43%	-0.76%
% of Gross Profit	816.13%	673.68%	1517.2%
Research & Development	$1.483M	$1.779M	$6.941M
YoY Change	-5.13%	23.72%	40.8%
% of Gross Profit	556.98%	759.15%	1520.36%
Depreciation & Amortization	$53.08K	$59.27K	$199.3K
YoY Change	47.89%	77.35%	67.99%
% of Gross Profit	19.93%	25.29%	43.65%
Operating Expenses	$3.657M	$3.399M	$13.87M
YoY Change	13.31%	2.15%	16.44%
Operating Profit	-$3.390M	-$3.165M	-$11.96M
YoY Change	90.01%	126.02%	19.19%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	$45.58K	$29.62K	$95.76K
YoY Change	-11.63%	14.58%	207.41%
Pretax Income	-$3.345M	-$3.135M	-$11.86M
YoY Change	93.04%	128.12%	18.6%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$3.345M	-$3.135M	-$11.86M
YoY Change	93.04%	128.12%	18.6%
Net Earnings / Revenue	-342.14%	-400.64%	-607.42%
Basic Earnings Per Share	-$0.14		-$0.65
Diluted Earnings Per Share	-$0.14	-$0.14	-$0.65
COMMON SHARES
Basic Shares Outstanding	23.96M shares	23.92M shares	18.12M shares
Diluted Shares Outstanding	24.00M shares		18.12M shares

Balance Sheet

Concept	2023 Q4	2023 Q3	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.681M	$5.322M	$5.322M
YoY Change	-64.92%	-52.23%	-52.23%
Cash & Equivalents	$2.681M	$5.322M
Short-Term Investments		$0.00	$0.00
Other Short-Term Assets	$21.32K	$263.8K	$263.8K
YoY Change	-93.45%	-11.09%	-11.09%
Inventory	$1.609M	$1.727M	$1.727M
Prepaid Expenses	$238.6K	$263.7K
Receivables	$543.4K		$0.00
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$5.093M	$7.313M	$7.313M
YoY Change	-43.2%	-39.94%	-39.94%
LONG-TERM ASSETS
Property, Plant & Equipment	$505.2K	$525.8K	$694.8K
YoY Change	50.89%	48.69%	29.88%
Goodwill
YoY Change
Intangibles	$84.00K	$89.58K
YoY Change	-20.99%	-19.94%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$729.4K	$784.4K	$784.4K
YoY Change	5.21%	21.26%	21.26%
TOTAL ASSETS
Total Short-Term Assets	$5.093M	$7.313M	$7.313M
Total Long-Term Assets	$729.4K	$784.4K	$784.4K
Total Assets	$5.822M	$8.097M	$8.097M
YoY Change	-39.73%	-36.85%	-36.85%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$760.0K	$685.1K	$685.1K
YoY Change	-11.8%	-26.15%	-26.15%
Accrued Expenses	$623.2K	$1.108M	$1.108M
YoY Change	31.74%	54.72%	54.72%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.383M	$1.793M	$1.793M
YoY Change	3.63%	-42.15%	-42.15%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$20.98K	$55.28K	$55.28K
YoY Change	-86.35%	-53.76%	-53.76%
Total Long-Term Liabilities	$20.98K	$55.28K	$55.28K
YoY Change	-86.35%	-53.76%	-53.76%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.383M	$1.793M	$1.793M
Total Long-Term Liabilities	$20.98K	$55.28K	$55.28K
Total Liabilities	$1.404M	$1.848M	$1.848M
YoY Change	-5.66%	-42.58%	-42.58%
SHAREHOLDERS EQUITY
Retained Earnings	-$66.00M	-$62.69M
YoY Change	25.57%	23.33%
Common Stock	$24.83K	$23.93K
YoY Change	52.91%	47.56%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$4.418M	$6.249M	$6.249M
YoY Change
Total Liabilities & Shareholders Equity	$5.822M	$8.097M	$8.097M
YoY Change	-39.73%	-36.85%	-36.85%

Cashflow Statement

Concept	2023 Q4	2023 Q3	2023
OPERATING ACTIVITIES
Net Income	-$3.345M	-$3.135M	-$11.86M
YoY Change	93.04%	128.12%	18.6%
Depreciation, Depletion And Amortization	$53.08K	$59.27K	$199.3K
YoY Change	47.89%	77.35%	67.99%
Cash From Operating Activities	-$3.809M	-$2.907M	-$12.89M
YoY Change	9.08%	-385.6%	71.38%
INVESTING ACTIVITIES
Capital Expenditures	$37.13K	$54.12K	$384.1K
YoY Change	222.54%	-181.76%	39.56%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$4.080K	$3.034M
YoY Change	-100.0%	-100.14%	-202.17%
Cash From Investing Activities	-$37.13K	-$50.04K	$2.650M
YoY Change	-346.41%	-98.35%	-181.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$1.205M	5.189M	$7.399M
YoY Change	-7768.9%		-38.46%
NET CHANGE
Cash From Operating Activities	-$3.809M	-2.907M	-$12.89M
Cash From Investing Activities	-$37.13K	-50.04K	$2.650M
Cash From Financing Activities	$1.205M	5.189M	$7.399M
Net Change In Cash	-$2.642M	2.232M	-$2.838M
YoY Change	-24.37%	-210.62%	-325.41%
FREE CASH FLOW
Cash From Operating Activities	-$3.809M	-$2.907M	-$12.89M
Capital Expenditures	$37.13K	$54.12K	$384.1K
Free Cash Flow	-$3.847M	-$2.961M	-$13.27M
YoY Change	9.78%	-373.15%	70.26%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent		usd
CY2023Q3	us-gaap	Deferred Revenue DeferredRevenue		usd
CY2022Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q3	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2022Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.63
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.65
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	15998567	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18121108	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-09-30
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--09-30
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-40439
CY2023	dei	Entity Registrant Name EntityRegistrantName	NeuroOne Medical Technologies Corporation
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	27-0863354
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	7599 Anagram Dr
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Eden Prairie
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	MN
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	55344
CY2023	dei	City Area Code CityAreaCode	952
CY2023	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value per share
CY2023	dei	Trading Symbol TradingSymbol	NMTC
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q1	dei	Entity Public Float EntityPublicFloat	24807523	usd
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	23962847	shares
CY2023	dei	Auditor Firm AuditorFirmId	23
CY2023	dei	Auditor Name AuditorName	Baker Tilly US, LLP
CY2023	dei	Auditor Location AuditorLocation	Minneapolis, Minnesota
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5322493	usd
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8160329	usd
CY2022Q3	us-gaap	Short Term Investments ShortTermInvestments	2981010	usd
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	33237	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	1726686	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	704538	usd
CY2023Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	263746	usd
CY2022Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	296649	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	7312925	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	12175763	usd
CY2023Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	89577	usd
CY2022Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	111892	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	169059	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	181355	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	525753	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	353599	usd
CY2023Q3	us-gaap	Assets Assets	8097314	usd
CY2022Q3	us-gaap	Assets Assets	12822609	usd
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	685104	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	927662	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1107522	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	715839	usd
CY2022Q3	us-gaap	Deferred Revenue DeferredRevenue	1455188	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	1792626	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	3098689	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	55284	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	119556	usd
CY2023Q3	us-gaap	Liabilities Liabilities	1847910	usd
CY2022Q3	us-gaap	Liabilities Liabilities	3218245	usd
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23928945	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23928945	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16216540	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16216540	shares
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	23929	usd
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	16217	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	68911778	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	60414959	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-62686303	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-50826812	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	6249404	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	9604364	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8097314	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	12822609	usd
CY2023	us-gaap	Revenues Revenues	1952441	usd
CY2022	us-gaap	Revenues Revenues	171169	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	1495924	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	241963	usd
CY2023	us-gaap	Gross Profit GrossProfit	456517	usd
CY2022	us-gaap	Gross Profit GrossProfit	-70794	usd
CY2023	nmtc	Revenue From Collaboration RevenueFromCollaboration	1455188	usd
CY2022	nmtc	Revenue From Collaboration RevenueFromCollaboration	1948872	usd
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	6926269	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	6979416	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6940686	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4929427	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	13866955	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	11908843	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-11955250	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-10030765	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	95759	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	31152	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-11859491	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-9999613	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-11859491	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-9999613	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.65
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.63
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	18121108	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15998567	shares
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	6553901	usd
CY2022	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	13350582	usd
CY2022	nmtc	Issuance Cost In Connection With Public Offering IssuanceCostInConnectionWithPublicOffering	1352280	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	104562	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	947212	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-9999613	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	9604364	usd
CY2023	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	6037500	usd
CY2023	nmtc	Issuance Of Common Stock In Connection With Public Offering And Atthemarket Offering Program IssuanceOfCommonStockInConnectionWithPublicOfferingAndAtthemarketOfferingProgram	2552656	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1071663	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1105457	usd
CY2023	nmtc	Share Repurchase For The Payment Of Employee Taxes ShareRepurchaseForThePaymentOfEmployeeTaxes	-119419	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-11859491	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	6249404	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-11859491	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-9999613	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	199266	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	118620	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	1105457	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	947212	usd
CY2023	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-32143	usd
CY2023	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	45571	usd
CY2022	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	11471	usd
CY2023	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-109832	usd
CY2022	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-107593	usd
CY2022	nmtc	Issuance Of Warrants In Connection With Zimmer Contract Amendment IssuanceOfWarrantsInConnectionWithZimmerContractAmendment	104562	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-33237	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-15099	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1022148	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	606251	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-32903	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	145540	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-247189	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	515438	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-1225313	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	1434817	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12886874	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7519534	usd
CY2023	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	1473419	usd
CY2022	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	3469539	usd
CY2023	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	4500000	usd
CY2022	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	500000	usd
CY2023	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	7500	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	384117	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	275226	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	2649964	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3244765	usd
CY2023	nmtc	Proceeds From Issuance Of Common Stock In Connection With Private Placement ProceedsFromIssuanceOfCommonStockInConnectionWithPrivatePlacement	8590156	usd
CY2022	nmtc	Proceeds From Issuance Of Common Stock In Connection With Private Placement ProceedsFromIssuanceOfCommonStockInConnectionWithPrivatePlacement	13350582	usd
CY2023	nmtc	Deferreds Offering Costs DeferredsOfferingCosts	-1071663	usd
CY2022	nmtc	Deferreds Offering Costs DeferredsOfferingCosts	-1327300	usd
CY2023	nmtc	Share Repurchases For The Payment Of Employee Taxes ShareRepurchasesForThePaymentOfEmployeeTaxes	119419	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7399074	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	12023282	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-2837836	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	1258983	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8160329	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	6901346	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	5322493	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8160329	usd
CY2023	nmtc	Unpaid Deferred Issuance Costsoffset In Prepaids And Other Assets UnpaidDeferredIssuanceCostsoffsetInPrepaidsAndOtherAssets	4631	usd
CY2023	nmtc	Operating Lease Right Of Use Asset Obtained In Exchange For Operating Lease OperatingLeaseRightOfUseAssetObtainedInExchangeForOperatingLease	97536	usd
CY2022	nmtc	Reclass Of Deferred Offering Costs To Additional Paidin Capital In Connection With Public Offering ReclassOfDeferredOfferingCostsToAdditionalPaidinCapitalInConnectionWithPublicOffering	24980	usd
CY2023Q3	us-gaap	Retained Earnings Unappropriated RetainedEarningsUnappropriated	62700000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Management’s Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2022Q3	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	230507	usd
CY2023Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	180311	usd
CY2022Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	73968	usd
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	pure
CY2023Q3	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	2981010	usd
CY2023Q3	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Loss HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss	2870	usd
CY2023Q3	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	2978140	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	1726686	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	704538	usd
CY2023	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7316	shares
CY2020Q3	nmtc	Royalty Minimum Payments Year One RoyaltyMinimumPaymentsYearOne	50000	usd
CY2021Q3	nmtc	Royalty Minimum Payments Year Two RoyaltyMinimumPaymentsYearTwo	100000	usd
CY2022Q3	nmtc	Royalty Minimum Payments Year Three RoyaltyMinimumPaymentsYearThree	150000	usd
CY2021Q2	us-gaap	Line Of Credit Facility Expiration Period LineOfCreditFacilityExpirationPeriod	P90D
CY2023Q3	us-gaap	Maturity Of Time Deposits MaturityOfTimeDeposits	P4Y
CY2023	nmtc	Royalty Fee RoyaltyFee	150000	usd
CY2019Q4	us-gaap	Payments For Rent PaymentsForRent	6410	usd
CY2021Q3	nmtc	Lease Space LeaseSpace	1162	sqm
CY2021Q3	nmtc	Lease Rental Expense LeaseRentalExpense	4241	usd
CY2022Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P2Y
CY2022Q4	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2024-12-31
CY2023	us-gaap	Royalty Expense RoyaltyExpense	171633	usd
CY2022Q3	nmtc	Royalty Fees RoyaltyFees	111132	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1107522	usd
CY2023	nmtc	Operating Cash Flows From Operating Leases OperatingCashFlowsFromOperatingLeases	134632	usd
CY2022	nmtc	Operating Cash Flows From Operating Leases OperatingCashFlowsFromOperatingLeases	130727	usd
CY2023	nmtc	Operating Lease Right Of Use Asset Obtained In Exchange For Operating Lease OperatingLeaseRightOfUseAssetObtainedInExchangeForOperatingLease	97536	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	169059	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	181355	usd
CY2023Q3	nmtc	Lease Liability LeaseLiability	184400	usd
CY2022Q3	nmtc	Lease Liability LeaseLiability	202895	usd
CY2023Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y4M24D
CY2022Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y4M24D
CY2023Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.078	pure
CY2022Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.069	pure
CY2023Q3	nmtc	Lessee Operating Lease Liability Payments Due Next Rolling Twelve Month LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonth	34070	usd
CY2023Q3	nmtc	Lessee Operating Lease Liability Payment Due In Rolling Year Two LesseeOperatingLeaseLiabilityPaymentDueInRollingYearTwo	139969	usd
CY2023Q3	nmtc	Lessee Operating Lease Liability Payment Due In Rolling Year Three LesseeOperatingLeaseLiabilityPaymentDueInRollingYearThree	21227	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	195266	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	10866	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	184400	usd
CY2023Q3	us-gaap	Short Term Lease Commitment Amount ShortTermLeaseCommitmentAmount	129116	usd
CY2023Q3	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	55284	usd
CY2023Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	1202778	usd
CY2022Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	400063	usd
CY2023Q3	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	343597	usd
CY2023	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
CY2021Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	134207	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	22315	usd
CY2022Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	111892	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	22315	usd
CY2023Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	89577	usd
CY2023Q3	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	860737000000	usd
CY2022Q3	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	538061000000	usd
CY2022Q3	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	1895000000	usd
CY2023Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	860737000000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	539956000000	usd
CY2023Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	334984000000	usd
CY2022Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	186357000000	usd
CY2023Q3	us-gaap	Property Plant And Equipment Other Net PropertyPlantAndEquipmentOtherNet	525753000000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Other Net PropertyPlantAndEquipmentOtherNet	353599000000	usd
CY2023	us-gaap	Depreciation Depreciation	176951	usd
CY2022	us-gaap	Depreciation Depreciation	96305	usd
CY2023Q3	us-gaap	Property Plant And Equipment Salvage Value PropertyPlantAndEquipmentSalvageValue	39643	usd
CY2023	us-gaap	Payments For Proceeds From Productive Assets PaymentsForProceedsFromProductiveAssets	-7500	usd
CY2023Q3	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	874382	usd
CY2022Q3	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	521368	usd
CY2023Q3	nmtc	Lease Liability Shortterms LeaseLiabilityShortterms	129116	usd
CY2022Q3	nmtc	Lease Liability Shortterms LeaseLiabilityShortterms	83339	usd
CY2023Q3	nmtc	Royalty Fees RoyaltyFees	104024	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	715839	usd
CY2023	nmtc	Intial Fee Payment IntialFeePayment	2000000	usd
CY2022Q3	nmtc	Milestone Payments Paid MilestonePaymentsPaid	3500000	usd
CY2023	us-gaap	Warrant Exercise Price Increase WarrantExercisePriceIncrease	3
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.029	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.535	pure
CY2023	nmtc	Expected Term ExpectedTerm	P5Y
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023	nmtc	Transaction Price Associated With The Development Agreement TransactionPriceAssociatedWithTheDevelopmentAgreement	5400000	usd
CY2023	nmtc	Initial Exclusivity Fee InitialExclusivityFee	2000000	usd
CY2023	nmtc	Milestone Payments MilestonePayments	3500000	usd
CY2023	nmtc	Fair Value Of Warrants FairValueOfWarrants	100000	usd
CY2023	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	1455188	usd
CY2022	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	1948872	usd
CY2021Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	8622	usd
CY2022	nmtc	Zimmer Agreement Amendment Related To Seeg Exclusivity Maintenance ZimmerAgreementAmendmentRelatedToSEEGExclusivityMaintenance	3395438	usd
CY2022	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	-1948872	usd
CY2022Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1455188	usd
CY2023	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	-1455188	usd
CY2023	nmtc	Product Revenue ProductRevenue	1952441	usd
CY2022	nmtc	Product Revenue ProductRevenue	171169	usd
CY2023	us-gaap	Advertising Expense AdvertisingExpense	173430	usd
CY2022	us-gaap	Advertising Expense AdvertisingExpense	270612	usd
CY2023	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	905108	usd
CY2022	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	780818	usd
CY2023	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	200349	usd
CY2022	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	166394	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1105457	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	947212	usd
CY2021Q4	nmtc	Reserved Share ReservedShare	420350	shares
CY2023	nmtc	Shares Outstanding Percentage SharesOutstandingPercentage	0.13	pure
CY2023Q1	nmtc	Option Plan Shares OptionPlanShares	129479	shares
CY2022Q1	nmtc	Option Plan Shares OptionPlanShares	1614538	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	152690	shares
CY2023	nmtc	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grants Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantsDateFairValue	0.88
CY2022	nmtc	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grants Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantsDateFairValue	0.76
CY2023	nmtc	Total Expenses Of Stock Option TotalExpensesOfStockOption	632315	usd
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1122560	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.89
CY2021Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y9M18D
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	127339	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	152690	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.5
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	35335	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	4.14
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1239915	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.4
CY2022Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	89295	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	469512	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.55
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	1000	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	3.78
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1708427	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.34
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y8M8D
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	20064	usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1708427	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	4.34
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y8M8D
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	20064	usd
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	1120768	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	5.08
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P7Y1M13D
CY2023Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	20064	usd
CY2023	nmtc	Exercise Price Of Underlying Options ExercisePriceOfUnderlyingOptions	0.89
CY2022	nmtc	Exercise Price Of Underlying Options ExercisePriceOfUnderlyingOptions	1.69
CY2023Q3	nmtc	Outstanding Stock Options Shares OutstandingStockOptionsShares	1682912	shares
CY2022Q3	nmtc	Outstanding Stock Options Shares OutstandingStockOptionsShares	1125710	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.574	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.535	pure
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y9M18D
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y7M6D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.037	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.023	pure
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	11384	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	443670	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	40624	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	414430	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	310728	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	331788	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	393370	shares
CY2023Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	1137983	shares
CY2023	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	1474119	usd
CY2023	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y9M18D
CY2023Q3	nmtc	Purchase Of Additional Shares PurchaseOfAdditionalShares	787500	shares
CY2023Q3	us-gaap	Common Stock Other Shares Outstanding CommonStockOtherSharesOutstanding	6037500	shares
CY2023	nmtc	Net Proceeds NetProceeds	5200000	usd
CY2022Q4	nmtc	Aggregate Offering Price AggregateOfferingPrice	14500000	usd
CY2022Q4	nmtc	Fixed Commission Rate FixedCommissionRate	0.03	pure
CY2023Q3	nmtc	Sale Of Stock Number Of Shares Issued SaleOfStockNumberOfSharesIssued	1439677	shares
CY2023	nmtc	Gross Proceeds GrossProceeds	2552656	usd
CY2023	nmtc	Issuance Costs IssuanceCosts	234725	usd
CY2023Q3	us-gaap	Common Stock Other Shares Outstanding CommonStockOtherSharesOutstanding	2560000	shares
CY2021Q3	nmtc	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVvestedNumber	7503808	shares
CY2021Q3	nmtc	Weighted Average Exercise Price Outstandings And Exercisable Beginning WeightedAverageExercisePriceOutstandingsAndExercisableBeginning	6.06
CY2021Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P3Y2M23D
CY2021Q3	nmtc	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod	350000	shares
CY2021Q3	nmtc	Exercise Price Per Warrant Issued ExercisePricePerWarrantIssued	3
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3
CY2021Q3	nmtc	Weighted Average Termyears Issuedin Shares WeightedAverageTermyearsIssuedinShares	P4Y10M2D
CY2021Q3	nmtc	Warrants Reverse Split Adjustment Correction WarrantsReverseSplitAdjustmentCorrection	-100	shares
CY2021Q3	nmtc	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Periods ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriods	-750364	shares
CY2021Q3	nmtc	Exercise Price Per Warrant Expired ExercisePricePerWarrantExpired	5.4
CY2021Q3	nmtc	Weighted Average Exercise Price Expired WeightedAverageExercisePriceExpired	5.4
CY2022Q3	nmtc	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVvestedNumber	7103344	shares
CY2022Q3	nmtc	Weighted Average Exercise Price Outstandings And Exercisable Beginning WeightedAverageExercisePriceOutstandingsAndExercisableBeginning	5.98
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P2Y8M4D
CY2023	nmtc	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Periods ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriods	-900918	shares
CY2023	nmtc	Weighted Average Exercise Price Expired WeightedAverageExercisePriceExpired	6.38
CY2023	nmtc	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Warrants Outstanding ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsOutstanding	6202426	shares
CY2023	nmtc	Weighted Average Exercise Price Outstanding WeightedAverageExercisePriceOutstanding	5.92
CY2023	nmtc	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerm	P2Y
CY2023Q3	nmtc	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVvestedNumber	6202426	shares
CY2023Q3	nmtc	Weighted Average Exercise Price Outstandings And Exercisable Beginning WeightedAverageExercisePriceOutstandingsAndExercisableBeginning	5.92
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P2Y
CY2023	us-gaap	Concentration Risk Customer ConcentrationRiskCustomer	One
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.077	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.077	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.017	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.03	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.008	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.007	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.296	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.31	pure
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	11657158	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	10164679	usd
CY2023Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	28352	usd
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	26447	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	63301	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	70399	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts	1780649	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	1314487	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	1107559	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	788790	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	688998	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	15632737	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	12058082	usd
CY2023Q4	nmtc	Deferred Tax Liabilities Fixed Asset And Other DeferredTaxLiabilitiesFixedAssetAndOther	204829	usd
CY2022Q4	nmtc	Deferred Tax Liabilities Fixed Asset And Other DeferredTaxLiabilitiesFixedAssetAndOther	140538	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	204829	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	140538	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	15427908	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	11917544	usd
CY2023Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	15633000	usd
CY2022Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	12058000	usd
CY2023Q3	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	15428000	usd
CY2022Q3	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	11918000	usd
CY2023Q3	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	40571000	usd
CY2022Q3	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	35408000	usd
CY2023Q3	nmtc	Deferred Tax Assets Tax Credit Carryforwards Research Federal DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal	1074000	usd
CY2022Q3	nmtc	Deferred Tax Assets Tax Credit Carryforwards Research Federal DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal	759000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	231968	usd
CY2023Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	231968	usd
CY2023	nmtc	Employees Compensation Percentage EmployeesCompensationPercentage	1	pure
CY2023	nmtc	Deferrals Percentage DeferralsPercentage	1	pure
CY2023	nmtc	Contributions Percentage ContributionsPercentage	0.03	pure
CY2023	nmtc	Internal Revenue Percentage InternalRevenuePercentage	1	pure
CY2022	nmtc	Contributions Amount ContributionsAmount	30697	usd
CY2023	dei	Local Phone Number LocalPhoneNumber	426-1383
CY2023Q3	us-gaap	Short Term Investments ShortTermInvestments		usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices		usd
CY2023	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices		usd
CY2022	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1		usd
CY2023	nmtc	Issuance Of Warrants In Connection With Zimmer Contract Amendment IssuanceOfWarrantsInConnectionWithZimmerContractAmendment		usd
CY2022	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment		usd
CY2022	nmtc	Share Repurchases For The Payment Of Employee Taxes ShareRepurchasesForThePaymentOfEmployeeTaxes		usd
CY2022	nmtc	Unpaid Deferred Issuance Costsoffset In Prepaids And Other Assets UnpaidDeferredIssuanceCostsoffsetInPrepaidsAndOtherAssets		usd
CY2022	nmtc	Operating Lease Right Of Use Asset Obtained In Exchange For Operating Lease OperatingLeaseRightOfUseAssetObtainedInExchangeForOperatingLease		usd
CY2023	nmtc	Reclass Of Deferred Offering Costs To Additional Paidin Capital In Connection With Public Offering ReclassOfDeferredOfferingCostsToAdditionalPaidinCapitalInConnectionWithPublicOffering		usd
CY2023Q3	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Gain HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain		usd
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount		shares
CY2022	nmtc	Operating Lease Right Of Use Asset Obtained In Exchange For Operating Lease OperatingLeaseRightOfUseAssetObtainedInExchangeForOperatingLease		usd
CY2023Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent		usd
CY2022	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2022	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue		usd
CY2022	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
CY2022	nmtc	Sharebased Compensation Aggregate Intrinsic Value Forfeited Cancelled SharebasedCompensationAggregateIntrinsicValueForfeitedCancelled		usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue		usd
CY2023	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
CY2023	nmtc	Sharebased Compensation Aggregate Intrinsic Value Forfeited Cancelled SharebasedCompensationAggregateIntrinsicValueForfeitedCancelled		usd
CY2021Q3	nmtc	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod		shares
CY2021Q3	nmtc	Weighted Average Exercise Price Exercise WeightedAverageExercisePriceExercise
CY2021Q3	nmtc	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price1 ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice1
CY2021Q3	nmtc	Weighted Average Termyears Exercisedin Shares WeightedAverageTermyearsExercisedinShares
CY2021Q3	nmtc	Exercise Price Per Warrant Reverse Split Adjustment Correction ExercisePricePerWarrantReverseSplitAdjustmentCorrection
CY2021Q3	nmtc	Weighted Average Exercise Price Reverse Split Adjustment Correction WeightedAverageExercisePriceReverseSplitAdjustmentCorrection
CY2021Q3	nmtc	Weighted Average Termyears Reverse Split Adjustment Correction WeightedAverageTermyearsReverseSplitAdjustmentCorrection
CY2021Q3	nmtc	Weighted Average Termyears Expired WeightedAverageTermyearsExpired
CY2023	nmtc	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod		shares
CY2023	nmtc	Exercise Price Per Warrant Issued ExercisePricePerWarrantIssued
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
CY2023	nmtc	Weighted Average Termyears Issuedin Shares WeightedAverageTermyearsIssuedinShares
CY2023	nmtc	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod		shares
CY2023	nmtc	Weighted Average Exercise Price Exercise WeightedAverageExercisePriceExercise
CY2023	nmtc	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price1 ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice1
CY2023	nmtc	Weighted Average Termyears Exercisedin Shares WeightedAverageTermyearsExercisedinShares
CY2023	nmtc	Weighted Average Termyears Expired WeightedAverageTermyearsExpired
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations		pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations		pure
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits		usd
CY2022Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits		usd
	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions		usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits		usd
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations		pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations		pure
CY2023	nmtc	Contributions Amount ContributionsAmount		usd
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001500198

Files In Submission

Name	View Source	Status
0001213900-23-096120-index-headers.html	Edgar Link	pending
0001213900-23-096120-index.html	Edgar Link	pending
0001213900-23-096120.txt	Edgar Link	pending
0001213900-23-096120-xbrl.zip	Edgar Link	pending
ex97-1_001.jpg	Edgar Link	pending
f10k2023ex21-1_neuroone.htm	Edgar Link	pending
f10k2023ex23-1_neuroone.htm	Edgar Link	pending
f10k2023ex31-1_neuroone.htm	Edgar Link	pending
f10k2023ex31-2_neuroone.htm	Edgar Link	pending
f10k2023ex32-1_neuroone.htm	Edgar Link	pending
f10k2023ex32-2_neuroone.htm	Edgar Link	pending
f10k2023ex97-1_neuroone.htm	Edgar Link	pending
f10k2023_neuroone.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nmtc-20230930.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
nmtc-20230930_lab.xml	Edgar Link	unprocessable
nmtc-20230930_pre.xml	Edgar Link	unprocessable
nmtc-20230930_def.xml	Edgar Link	unprocessable
f10k2023_neuroone_htm.xml	Edgar Link	completed
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
nmtc-20230930_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NMTC
NEUROONE MEDICAL TECHNOLOGIES Corp Stock $nmtc

2023 Q4 Form 10-K Financial Statement

#000121390023096120 Filed on December 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NMTC NEUROONE MEDICAL TECHNOLOGIES Corp Stock $nmtc

2023 Q4 Form 10-K Financial Statement

#000121390023096120 Filed on December 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NMTC
NEUROONE MEDICAL TECHNOLOGIES Corp Stock $nmtc